BioArctic moves forward with its candidate for Parkinson’s

BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.

FDA:s rådgivande vaccinmöte inställt – utan förklaring

Ett årligt möte mellan FDA och deras rådgivande vaccinkommitté ställs in.

Hon är MSD:s nya svenska vd

Birgitta Wikman Erlandson har utsetts till vd för MSD Sverige där hon de senaste året varit affärsområdeschef för vaccinavdelningen.

Come see us at the upcoming events!

We have some upcoming events where you can see our latest products live!

Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Column: ”Authentic leadership and clear mandates pave the way for more female CEOs”

”I believe that the aspect of having clear mandates and titles on the one hand and women progressing into top positions must be explored further”, Helena Strigå...

Achieve Efficient, Fast Targeting of Your Sample

Step into the future of imaging technology with VersaXRM 730.

Individual DNA passport could result in fewer drug side effects

You may be required to show a DNA passport when you pick up medicines at the pharmacy in the future. According to a new study, patients might suffer 30% fewer s...

He is zooming in on topical preparations

According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting ap...

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

Tio life science-projekt får miljonanslag – ny utlysning öppnar

En rad life science-projekt har fått miljonanslag i ett svenskt proof of concept-program. 13 januari öppnar en ny utlysning.

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

Inget statligt stöd för fetmaläkemedel – aktien för läkemedelsjättar pressas

Trump-administrationen slopar Bidens förslag om att om att inkludera fetmaläkemedel i sjukförsäkringen Medicare. Det innebär ett bakslag för Novo Nordisk och El...

Gothenburg, the city of life science – We are ‘Little Boston’

Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...

A small thing that can solve your problems

If you are in need of a compact valve. Look no further! We have the VOVK

Column: Why there cannot be a complete cure for cancer – but there is certainly another way!

"Is there a new way we need to be thinking about how to prevent cancer?" Lucy Robertshaw reflects upon which is the smartest way to beat cancer.

CSL Behring: Nya terapier kräver nya betalningsmodeller

DEBATT: NT-rådets beslut att inte rekommendera en genterapi för hemofili på grund av kostnad och osäker effektlängd belyser vikten av att terapier mot sällsynta...

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

TFS Trial Form Support AB

Amrop Malmö AB

FDA godkänner första icke-opioida smärtstillaren på över 20 år

För första gången på flera decennier har en ny typ av läkemedel mot akut smärta som inte är en opioid godkänts i USA.

Swedish pavilion with healthcare companies at Ukraine fair – “Ukraine is being rebuilt right now”

Private companies and public authorities are both needed in the reconstruction of Ukraine, said Minister for Health Care, Acko Ankarberg Johansson, in her openi...

Bio Europe to Stockholm – ”The Swedish ecosystem is now taking the opportunity”

The international life science conference Bio Europe is coming to Sweden for the first time in November. The conference, whose program takes inspiration from AB...